During Q208, Singapore achieved its goal of making biomedical sciences a ‘key pillar’ of its economy.The sector now accounts for over one-tenth of manufacturing output, according to the country’sEconomic Development Board (EDB). Due to regional rivals eroding its traditional production industries– electronics, rubber and chemicals – the city-state is committed to increasing its involvement in the highvaluebiosciences. BMI believes that this strategy is sound and sustainable, as recently shown by the factthat two more multinationals are establishing production plants in Singapore.
In 2009, biomedical companies made fixed asset investments of more than US$800mn in Singapore. Inthe whole of 2008, US$500mn
2009年には、生体医学企業は、シンガポール内で、アメリカドルで800mn以上もの固定資産投資を行った。2008年全体では500mn程度だった。
2009年、バイオメディカル企業は、シンガポールにおいてUS8億ドル以上の固定資産投資を行った。2008年全体では、シンガポールのバイオメディカル部門の外国人プレーヤーによってUS5憶ドルが投資された。
2009年、生物医学企業はシンガポールに8億ドルを越える固定資産投資を行った。2008年には5億ドル・・・
was invested by foreign players in Singapore’s biomedical sciences sector,according to Singapore’s EDB, with biosciences contributing US$13mn to total manufacturing output. Inthe previous year, sector expenditure topped US$760mn, with staff numbering over 11,500, double thenumber in 2000. Singapore’s biosciences industry presently boasts the presence of 50 global companies(including Bayer, Takeda, Millipore and Schering-Plough), which are often involved in partnershipswith some 30 local public-sector academic and research institutes. By 2015, the government is targetingUS$17bn in biosciences manufacturing output (up from US$4.56bn in 2000), with the support of its costsharingof wages and training programme.
Apr 08, both Switzerland-based Alcon and US drugmaker Wyeth announced plans to increasetheir Singaporeanfootprints